Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 32

Results For "data"

1957 News Found

Sound's for hearing loss: Co's drug wins FDA breakthrough tag for Meniere’s disease
Clinical Trials | December 03, 2025

Sound's for hearing loss: Co's drug wins FDA breakthrough tag for Meniere’s disease

Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss


LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea
Drug Approval | December 03, 2025

LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea

Presbyopia, the age-related loss of near vision, could soon be treated successfully


Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval
News | December 03, 2025

Cleveland Diagnostics’ IsoPSA test for prostate cancer detection gains FDA approval

Now a test that offers new precision in prostate cancer detection


Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis
News | December 01, 2025

Sun Pharma introduces Ilumya in India for treatment of plaque psoriasis

Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials


Roche expands Veeva partnership with global rollout of AI-driven Vault CRM
Digitisation | December 01, 2025

Roche expands Veeva partnership with global rollout of AI-driven Vault CRM

Roche says the move marks a step forward in its digital transformation strategy


Global measles deaths plunge but cases surge, says WHO
Healthcare | December 01, 2025

Global measles deaths plunge but cases surge, says WHO

In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic


InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China
Clinical Trials | November 30, 2025

InnoCare Pharma launches global Phase II trial of TYK2 inhibitor for prurigo nodularis in China

Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders


Renalys Pharma reports major phase III success for Sparsentan in Japanese IgA nephropathy patients
Clinical Trials | November 28, 2025

Renalys Pharma reports major phase III success for Sparsentan in Japanese IgA nephropathy patients

The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio